HUMANISED ANTI-IL-10 ANTIBODIES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Russian patent published in 2016 - IPC C07K16/24 A61K39/395 

FIELD: biochemistry.

SUBSTANCE: disclosed is a humanised antibody or fragment thereof capable of binding to interleukin-10 (IL-10). Antibody binds to same region of IL-10, and that α IL-10 receptor is not able to bind to IL-10 when IL-10 is associated with IL-10 receptor. Furthermore, antibody binds to IL-10 in homodimeric form by binding with discontinuous epitope comprising residues of both monomers. Before CDR1 heavy chain antibody should be FSXA amino acid sequence, and CDR2 heavy chain follows XXXXXXXNS amino acid sequence; said sequences are involved in binding with discontinuous epitope. Antibody is used in methods of determining presence of IL-10 in a sample, diagnosis, treating or preventing a medical conditions associated with high level or activity of IL-10, such as systemic lupus erythematosus.

EFFECT: invention enables to bind to functionally active IL-10 with much higher affinity than with monomers of IL-10, in which there is only part of discontinuous epitope.

32 cl, 16 dwg, 8 tbl, 8 ex